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A general feature of a tumor is that it comprises tumor cells and stroma containing immune
cells, fibroblasts, matrix and blood vessels. Therefore, it is not surprising that in this special issue,
the mechanisms of mesothelioma heterogeneity have been addressed extensively at the level of
tumoral cells, highlighting differences in genetic alterations [1–5] or temporal differences during tumor
progression [2].
In this context, it is worth noting that besides the two pathways widely mutated in cancer, namely,
cell cycle control (cyclin-dependent kinase Inhibitor 2A, CDKN2A) and genome integrity (TP53),
there are also two specific pathways frequently mutated in MPM, namely, the neurofibromatosis type 2
(NF2)/Hippo and the Breast-Repair-associated-Cancer 1(BRCA)-associated protein 1 (BAP1) pathways.
With regard to NF2/Hippo, as pointed out by Sato and Sekido [5], it is intriguing that if their
downstream targets are activated yes-associated protein 1 (YAP1) and transcriptional co-activator with
PDZ domain-binding motif (TAZ), no mutations that result in their activation have been observed
in mesothelioma. Mutations that result in their constitutive activation would involve mutations
of individual or multiple phosphorylation sites, allowing YAP and TAZ retention in the cytosol
preventing activation of YAP/TAZ-dependent transcription. However, there are well-known examples,
like Phosphatase and tensin homolog (PTEN), where loss of control of phosphorylation targets are
tumorigenic. In addition, both YAP and TAZ have multiple phosphorylation sites so it is likely that
deregulation of the upstream kinase would be more efficient. As reviewed by Sato and Sekido [5],
YAP has been largely investigated in mesothelioma, however, Hagenbeeck et al. [6] recently noted that
YAP and TAZ have slightly different transcriptional profiles, whereby TAZ increases, for example,
the expression of wound-healing-associated, pro-tumorigenic genes such as Arginase 1. This gene was
one of the genes with the highest expression in tissues from asbestos exposed mice and remained high
in tumors [7]. Therefore, there remains an open question about a possibly synergistic mode of action
where TAZ modifies the tumor microenvironment while YAP promotes tumor cell proliferation.
While the understanding of the mechanisms behind the contribution of the NF2/Hippo pathway
to mesothelioma has progressed greatly since the seminal observation of the high frequency of NF2
mutations in mesothelioma [8,9], understanding of the mechanisms underlying BAP1 are less advanced.
This is to be expected as this mutational event was discovered more recently [10,11]. Interestingly, in the
analysis of TCGA samples, BAP1 status was associated with differential gene expression [12] as
originally described in Drosophila (fruit fly). Here the BAP1 homolog was responsible for repression
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of HOX genes in the fly embryo while also increasing HOX expression in particular tissues in central
nervous system [13].
Because of the known role of long non-coding RNA (lncRNA) in assembling and controlling
transcriptional complexes (reviewed in [14]), it would be of interest to explore if lncRNA
associated with BAP1 show differential transcriptional profiles that are associated with better clinical
outcome [12,15]. In fact, their expression may, for example, point to a given cell of origin and
commitment to epithelial differentiation phenotype. This was observed in patients’ samples by
Felley-Bosco and Rehrauer [16] for FENDRR, a lncRNA found to be overexpressed in tumors
developing in mice after exposure to asbestos fibers, and which also clusters with better outcomes in
human mesothelioma patients [12]. Similarly, Meg3, another lncRNA found to be overexpressed in
tumors developing in mice after exposure to asbestos fibers [16] is overexpressed in TCGA cluster 1,
which was characterized by better overall survival [12] compared to the other 3 clusters of patients
with different transcription profiles.
Other non-coding RNA of interest that have been extensively reviewed [17] include microRNA
(miR), which have been deeply investigated for diagnostic and prognostic purposes and reviewed by
Martinez-Rivera et al. [17]. They highlight the challenges to come with the investigation of circulating
miR in total plasma/serum vs exosomal vesicles. In this context, additional complexity has been
recently added by the investigation of expression obtained through RNA-seq data. This has revealed
how classical analysis approaches may miss isomiRs [18].
Even though peritoneal mesothelioma is less frequent compared to pleural mesothelioma,
the mutational landscape is similar, with BAP1 frequently being mutated [19]. The reported case
of long-survivor peritoneal mesothelioma by Serio et al. [4] did not display any of the mutations in the
frequently mutated genes BAP1, CDKN2A, or NF2 and was treated with oxaliplatin, a known inducer
of immunogenic cell death [20]. Therefore, if more tissue were available from mesothelioma patients
treated with oxaliplatin, it would be interesting to establish a cohort where potential neoantigens
generation and immune response could be explored.
Heterogeneity in the tumor environment has been widely reviewed [1,21] with more emphasis
on heterogeneity in immune cell content in the tumor microenvironment, which is also in line with
the intensive exploration of immunotherapy in mesothelioma treatment [22]. Minnema-Luiting
and colleagues [21] emphasize how several studies point to the important role of M2-polarized
macrophages in mesothelioma. Interestingly, according to the interactive web-based platform
https://www.cri-iatlas.org/ [23], which was established as an analytic tool for studying the
interactions between tumors analyzed in TCGA and the immune microenvironment, the best
relationship with leukocytes tumoral infiltration is observed for the signature known as the
“macrophage regulation” (Figure 1a) This is better when compared to the relationship with the
signature called the “IFN-gamma response” (Figure 1b). Altogether, these observations point to the
macrophage population as a major regulator of the immune system in mesothelioma.
Besides immune cells, the mesothelioma tumor environment also contains cancer-associated
fibroblasts and a matrix, likely produced by the tumor, immune cells and fibroblasts themselves.
However, both cancer-associated fibroblasts and the matrix, which are likely to be major contributors
of stiffness-dependent effects such as modulation of YAP/TAZ transcriptional regulators [24], remain to
be explored.
As highlighted by Tolani et al. [1], a stem cell signaling pathway that should be further explored
is the Notch signaling pathway, especially since it is expressed in patients with predominantly
non-epithelioid histologies with poorer outcomes [12] compared to patients in cluster 1, who are
characterized by better overall survival.
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Figure 1. Mesothelioma leukocyte fraction is highly correlated with the signature “Macrophage 
regulation” (a) compared with the correlation with IFN-gamma response (b). These graphics were 
obtained using the interactive web-based platform https://www.cri-iatlas.org/ [23]. 
Jean and Jaurand wrote a timely, comprehensive review on how experimental murine 
mesothelioma models [25] have helped in understanding the mechanism of mesothelioma 
development using tissue specific targeted gene disruption using injections of AdenoCre or 
exposure to asbestos fibers. Genetic alteration signatures observed in mice exposed to asbestos 
resemble what is observed in human clinical samples and is mostly associated with copy number 
variations. This is in line with the lack of detection of a specific point mutation signature 
(https://cancer.sanger.ac.uk/cosmic/signatures), besides aging, in the two-human high-through-put 
studies [12,26]. These models are useful for the investigation of other relevant changes, such as 
epigenetic modifications. 
Finally, yet importantly, Colin et al. [27] developed a human orthotopic (intrapleural) xenograft 
model in athymic mice, where it is possible to investigate the role of macrophage migration 
inhibiting factor (MIF) because this particular model expresses both MIF and its functional receptor 
CD74. The authors show the presence of M2-polarized macrophages in this model. Therefore, the 
model allows not only investigating the role of MIF but also testing drugs acting on macrophage 
polarization, thus allowing testing of the effect of macrophage polarization on tumor growth.  
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